(Interpretation: from the current vantage point in May 2026, "next year" refers to 2027. However, the evidence base we have is primarily about active pipelines and major 2026 decisions. I focus on diseases with clear late‑stage pipelines and regulatory signals indicating imminent or near‑term breakthroughs.)

Across late‑stage pipelines, several disease areas stand out for near‑term transformative therapies:

• Alzheimer's disease and related dementias,

• Genetic and ultra‑rare diseases via gene therapy/CRISPR,

• Metabolic diseases (obesity and NASH), and

• Select cancers leveraging next‑generation cell and targeted therapies.

1. Alzheimer's Disease and Other Dementias

Why Alzheimer's is central

• Existing disease‑modifying antibodies (lecanemab/Leqembi and donanemab/Kisunla) have already been approved for early Alzheimer's, slowing cognitive decline by ~25–30% compared with placebo in trials.[1][7][8]

• BrightFocus' 2026 forecast notes that Leqembi and Kisunla are the first FDA‑approved drugs to directly target the underlying cause (amyloid) rather than just symptoms, and anticipates additional treatments and delivery innovations in the near term.[1]

• The same forecast highlights an FDA decision expected in May 2026 on at‑home starter doses of Leqembi, signalling regulatory openness to broader access and more flexible delivery models.[1]
  Pipeline momentum into 2027

• The Alzheimer's Association reports eight Phase 3 trials with primary completion dates in 2026 and 29 Phase 2 trials behind them, suggesting a wave of data and potential filings in 2027.[10]

• There is growing focus on tau‑targeting therapies and combination strategies (amyloid + tau), as well as gene‑targeted interventions and antisense oligonucleotides for familial forms. While not all will succeed, the density of late‑stage programs makes Alzheimer's highly likely to see additional breakthroughs in 2027.

1. Genetic and Ultra‑Rare Diseases (Gene Therapy / CRISPR)

Evidence of 2026–2027 momentum

• 2025 was a breakthrough year for gene therapy approvals; commentary from science outlets (e.g., LiveScience) expect 2026–2027 to bring "more exciting developments" as platforms mature, manufacturing scales, and regulatory familiarity grows.[2][3]

• The Innovative Genomics Institute's 2026 update on CRISPR clinical trials highlights a growing number of Phase 2/3 trials across hematologic, ophthalmic, and metabolic indications, with early readouts showing high response rates and durable benefit.[6]

• The Breakthrough Prize 2026 gene therapy laureates underscore the clinical impact of gene replacement in inherited retinal disease (RPE65 mutation), where vision can be restored by a one‑time treatment, demonstrating the potential magnitude of benefit for other monogenic disorders.[2]
  Disease areas likely to benefit most

• Hematologic diseases: Sickle cell disease and beta‑thalassemia already have CRISPR‑based therapies with high cure‑like rates in late‑phase or early commercial use; 2027 is likely to see geographic expansion, label expansions, and follow‑on therapies.[6][9]

• Inherited retinal diseases: Additional gene therapies for other retinal targets are moving through later‑stage development following the RPE65 precedent.[2]

• Ultra‑rare metabolic and immune disorders: Gene replacement or editing approaches are entering mid‑to‑late stage trials, with 2026–2027 readouts expected to drive approvals in select indications.

1. Metabolic Disease: Obesity, Diabetes, and NASH

GLP‑1/GIP agonists and beyond

• Drugs like tirzepatide (dual GIP/GLP‑1 agonist) and other next‑generation incretin‑based agents are already transforming obesity and type 2 diabetes control, with robust weight loss and glycemic improvements.[3][4]

• Payer and manufacturer communications in 2026 highlight multiple Phase 3 trials in NASH/MASH (metabolic dysfunction–associated steatohepatitis), with some reporting substantial improvements in liver histology and fibrosis compared to placebo.[3][4]
  Likely 2027 breakthrough areas

• NASH/MASH: Given the high global prevalence and absence of widely adopted disease‑modifying drugs, positive Phase 3 data from GLP‑1/GIP agents or novel mechanisms could make NASH one of the biggest 2027 treatment‑breakthrough stories.

• Cardiovascular risk reduction in obesity/diabetes: Large CV outcomes trials of GLP‑1/GIP drugs are reading out around 2026–2027; if they confirm major MACE (major adverse cardiovascular event) reductions, guideline shifts and broad insurance coverage will follow, materially changing standard of care.

1. Oncology: Next‑Generation Targeted and Cell Therapies

Where oncology breakthroughs are clustering

• The AACR blog on FDA oncology approvals in early 2026 records nine approvals across blood cancers, pancreatic cancer, and other malignancies just in Q1 2026, showing the pace of innovation.[5]

• Dana‑Farber's "Ten Cancer‑Related Breakthroughs" highlights:

  • Next‑generation CAR T‑cell therapies expanding into more hematologic malignancies and being trialed in solid tumors,

  • mRNA‑based personalized cancer vaccines targeting neoantigens, and

  • immunotherapy combinations pushing survival gains in melanoma, lung cancer, and more.[3]
    Implications for 2027

• Given the density of Phase 2/3 trials and early‑2026 approvals, expect 2027 breakthroughs in:

  • additional CAR‑T indications (especially multiple myeloma and lymphomas),

  • mRNA cancer vaccines (e.g., adjuvant melanoma, high‑risk solid tumors),

  • novel targeted therapies for breast cancer (e.g., SERDs like camizestrant) and other tumor types.[3][5]

Counterarguments and Uncertainty

• High attrition rates: Even in late‑stage trials, many assets fail to show sufficient benefit or acceptable safety; not all pipeline excitement will translate into approvals.

• Access and affordability: Gene therapies and advanced biologics may be priced in the hundreds of thousands or millions of dollars per treatment, limiting real‑world impact without reimbursement and policy solutions.

• Regulatory risk: Safety signals (e.g., amyloid‑related imaging abnormalities in Alzheimer's drugs, off‑target effects in gene editing) can delay or derail approvals.

Summary of Where Big Breakthroughs Are Most Likely

Most likely "biggest breakthroughs" in the near term (next year / 2027):

1. Alzheimer's disease and related dementias

   • Additional disease‑modifying antibodies and possibly new mechanisms (tau, combination approaches).

   • Expanded indications and earlier‑stage use, leveraging maturing biomarker diagnostics.

2. Genetic and ultra‑rare diseases

   • Gene therapies (including CRISPR‑based) for hematologic, retinal, and metabolic disorders moving from initial approvals to broader use and new indications.

3. Metabolic disease (obesity, diabetes, NASH)

   • New or broadened approvals of incretin‑based drugs that not only manage weight and glycemia but also modify liver disease and cardiovascular risk.

4. Select cancers

   • CAR‑T and cell therapies into new hematologic malignancies and potentially solid tumors; mRNA cancer vaccines and next‑generation targeted therapies for high‑burden cancers.